Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway.
Pelin AydinZeynep Berna Aksakalli MagdenSevgi Karabulut UzunçakmakHamza HaliciNurullah AkgunAli Sefa MendilBehzad MokhtareElif CadirciPublished in: Lung (2022)
We suggest that avanafil may prevent the progression of ALI and be effective in its treatment. We hope that this study will be supported by future clinical studies to yield a new indication for avanafil.